pizuglanstat

TAS-205 (INN: pizuglanstat) is a selective small molecule inhibitor of hematopoietic prostaglandin D synthase (HPGDS), an enzyme involved in the production of prostaglandin D2, which mediates inflammation and muscle tissue necrosis. By inhibiting HPGDS, TAS-205 aims to reduce the inflammatory response and slow the decline in motor function in patients with Duchenne muscular dystrophy (DMD), regardless of dystrophin gene mutation type. Preclinical studies demonstrated improved locomotor activity and reduced muscle necrosis in dystrophin-deficient mice. Clinical trials have shown that TAS-205 is safe and may delay muscle deterioration in DMD patients[1][2][3][5][6][7].

Other names

pizuglanstat